Hisamitsu Pharmaceutical Co., Inc.
HTSUFOTCHealthcare
$29.00
+$0.00(+0.00%)
Market Cap$2.0B
P/E Ratio—
52W High$32.3
52W Low$28.94
Hisamitsu Pharmaceutical Co., Inc.（HTSUF）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · HTSUF · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2026-02 | 2025-02 | 2024-02 | 2023-02 | 2022-02 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $163.49B | $156.01B | $141.71B | $128.33B | $120.19B |
| Cost of Revenue | $67.10B | $64.81B | $62.73B | $55.63B | $50.13B |
| Gross Profit | $96.40B | $91.20B | $78.97B | $72.70B | $70.07B |
| Gross Margin %(computed) | 58.96% | 58.46% | 55.73% | 56.65% | 58.30% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $8.61B | $9.79B | $10.61B |
| G&A Expenses | $0.00B | $26.53B | $25.29B | $23.22B | $20.58B |
| Total Operating Expenses | $78.43B | $72.30B | $65.80B | $61.10B | $60.73B |
| Operating Income | $17.97B | $18.89B | $13.17B | $11.60B | $9.34B |
| Operating Margin %(computed) | 10.99% | 12.11% | 9.29% | 9.04% | 7.77% |
| Interest Income | $2.37B | $2.75B | $2.56B | $0.89B | $0.15B |
| Interest Expense | $0.02B | $0.02B | $0.02B | $0.01B | $0.02B |
| Income Before Tax | $23.72B | $28.69B | $19.19B | $16.11B | $12.96B |
| Income Tax Expense | $4.12B | $6.38B | $4.75B | $3.99B | $3.09B |
| Net Income | $19.22B | $21.76B | $13.97B | $11.74B | $9.66B |
| Net Margin %(computed) | 11.75% | 13.95% | 9.86% | 9.15% | 8.04% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $269.27 | $295.57 | $181.61 | $148.00 | $118.92 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.08B | 0.08B | 0.08B |
| EBITDA | $25.04B | $35.05B | $24.38B | $16.55B | $17.30B |
| EBITDA Margin %(computed) | 15.32% | 22.46% | 17.20% | 12.90% | 14.39% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · JPY · B
深入了解Hisamitsu Pharmaceutical Co., Inc.
关于Hisamitsu Pharmaceutical Co., Inc.（HTSUF）损益表
Hisamitsu Pharmaceutical Co., Inc.（HTSUF）损益表数据来源于SEC Form 10-K及10-Q申报文件。2026财年，HTSUF实现营收$163.49B，毛利润$96.40B（毛利率58.96%），净利润$19.22B（净利率11.75%）。
常见问题
HTSUF · 4 问Hisamitsu Pharmaceutical Co., Inc.（HTSUF）2026财年营收为$163.49B，同比up4.8%。
HTSUF revenueHTSUF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09